Pharma & Biotech Global Week in Review 28 Sept 2011 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

 

Highlights this week included:

US: CAFC: Patent exhaustion does not apply to genetically engineered seed: Monsanto Co. v. Bowman (Patent Docs) (IPBiz) (Patently-O)

Australia: Divided Senate Committee urges rejection of Gene Patents Bill (Patentology) (BIOtechNOW) (ipwars.com) (IP Whiteboard)

 

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

 

General

What the 2001 Doha Declaration changed (KEI)

Health Impact Fund – Raising issues of distribution, IP rights and alliances (IP Watch)

Australia: Divided Senate Committee urges rejection of Gene Patents Bill (Patentology) (BIOtechNOW) (ipwars.com) (IP Whiteboard)

China: Sino-U.S. investment vehicle to bring U.S. medicines into Chinese pharmaceutical market (IP Dragon)

EU: Dawn of a new era? The AG’s opinion in Georgetown and Medeva (The SPC blog)

Hungary: Repeatedly filed request for preliminary injunction – micronized active ingredient (EPLAW)

Indonesia pharma patents and generic manufacture (IP Komodo)

South Africa: Traditional Knowledge Bill debate – your views needed (Afro-IP) (Afro-IP) (Afro-IP)

UK: Second round consultation on Patent Box proposal (including SPCs) ends (The SPC Blog)

US: CAFC: Patent exhaustion does not apply to genetically engineered seed: Monsanto Co. v. Bowman (Patent Docs) (IPBiz) (Patently-O)

US: President’s deficit reduction plan seeks to reduce exclusivity period for biologics and prohibit pay-for-delay deals (Patent Docs)

US: DHHS Secretary Donna Shalala to Rep Jan Schakowsky in 2000, on WHO access to fed funded patent rights (KEI)

US: AMP v USPTO: The latest developments (Patent Law Practice Center)

US: ISIS Pharmaceuticals files patent infringement suit against Santaris based on its sale of drug discovery services and drug candidates including antisense compounds that inhibit beta-catenin production (Patent Docs)

US: False marking claim dismissed for generalised pleading: Simonian v Astellas Pharma (Chicago Intellectual Property Law Blog)

 

Products

Amoxicillin – India: Japanese pharmaceutical company sues for patent infringement in Delhi to protect its French markets: Astellas Pharma v Micro-Labs (Spicy IP)

Angiomax (Bivalirudin) – US: It ain’t over ‘til it’s over – The ANGIOMAX PTE battle takes yet another new turn (FDA Law Blog)

Eloxatin (Oxaliplatin) – US: Sanofi secures injunction blocking Sun from marketing generic Eloxatin (Patent Docs)

Fentora (Fentalyn) – US: Cephalon files patent infringement suit against Sandoz following Para IV certification (Patent Docs)

Fosamax (Alendronic acid) and Lescol (Fluvastatin) – Spain: Should national nullity proceedings be stayed until parallel EPO opposition proceedings are resolved? (Kluwer Patent Blog)

Gabitril (Tiagabine) – US: Cephalon files suits against Sun Pharma. in New Jersey and Michigan in response to Para IV certification (Patent Docs)

Glivec (Imatinib) – India: Novartis Glivec patent case: preliminary objection (Spicy IP)

Lovenox (Enoxaparin) – US: Momenta files patent infringement complaint against Amphastar in response to impending launch of generic Lovenox (Patent Docs)

Lumigan (Bimatoprost) – US: Validity of Allergan Lumigan patents upheld (Patent Docs)

Nexavar (Sorafenib) – India: Natco pushes ahead with bid to compulsorily licence anti-cancer drug from Bayer (IP Whiteboard)

Nexavar (Sorafenib) – India: Tracking the litigation around Bayer’s Nexavar patent in India (Spicy IP)

PhosLo (Calcium acetate) – US: Fresnenius Medical Care files patent infringement complaints in E D New York and Massachusetts against Invagen in response to Para IV challenge (Patent Docs)

Solodyn (Minocycline) – US: Medicis secures permanent injunction, settling Solodyn dispute with Aurobindo (Patent Docs)

Valsartan – France: Cour d’appel rules on Valsartan SPC: Actavis v Novartis (The SPC Blog)

Xyzal (Levocetirizine dihydrochloride) – US: District Court vacates 30-month stay extension; says stay only applies to ANDAs containing a Paragraph IV certification: Sunovion v Sandoz (FDA Law Blog)

Zyprexa (Olanzapine) – Netherlands: Court of Appeal The Hague holds Lilly’s Olanzapine patent and SPC valid: Eli Lilly v Ratiopharm (EPLAW)

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: